DHC's Morse and Fiedorowicz: Analytical Considerations for Gene-Modified Hematopoietic Stem and Progenitor Cell Therapies: Part 1

May 10, 2024
Categories
BPI BioProcess International image online

Today DHC Principal Brent Morse and Senior Consultant Alicja Fiedorowicz published Part 1 — In-Process and Drug Product Control of Analytical Considerations for Gene-Modified Hematopoietic Stem and Progenitor Cell Therapies in BioProcess International.

Genome-modified hematopoietic stem and progenitor cell (GM-HSPC) therapies represent a significant frontier in the realm of personalized medicine, holding the promise of targeted interventions for a spectrum of disorders far beyond hematological conditions. Development of these therapies is tied intricately to the rich history of and advancements in hematopoietic stem cell (HSC) grafts, which have served as the cornerstone for our understanding of hematopoiesis and bone-marrow transplantation (1).

The journey toward gene-edited stem cell therapies began...

...continue reading the full article here.

Related Posts

Join the Quarter Horse Newsletter

We’ll send you a quarterly newsletter all things DHC!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.